Pharma Action Opens Crude Heparin Factory
The opening ceremony for Pharma Action's new factory located in the Aurea industrial park took place earlier this week. The factory, which will produce the pharmaceutical intermediate crude heparin, will start production in the 4th Quarter of 2014. This will signify the possibility to process around 60% of Europe's traceable heparin raw material in Germany. Toennies, a global company with many years of experience and expertise in the meat industry, fulfills all international requirements with respect to quality and hygiene. This expertise also ensures the complete traceability of the heparin raw material (pig intestinal mucosa). The opening was attended by Garrelt Duin, Northrhine-Westphalia's Minister for Economic Affairs, as well as numerous mayors and other political and economic decision makers.
Northrhine-Westphalia's Minister for Economic Affairs Garrelt Duin praised the collaboration between Toennies and Pharma Action: "The opening of the Pharma Action Aurea factory is a good example of how companies with different focuses can come together to exploit synergy effects to enter into new markets. The collaboration between Toennies and Pharma Action is an innovative accomplishment, which gives a boost to the economy in Ostwestfalen."
The event concluded with a keynote lecture about heparin and its medicinal applications given by Professor Dr Susanne Alban, Professor of Pharmaceutical Biology and head of the Pharmaceutical Institute at the Christian-Albrechts-University in Kiel. Her talk summarised current ressearch on the area and gave a perspective on relevant topics for the industrial manufacture of heparin.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.